nodes	percent_of_prediction	percent_of_DWPC	metapath
Apomorphine—ADRA1B—vas deferens—prostate cancer	0.0691	0.488	CbGeAlD
Apomorphine—CALY—testis—prostate cancer	0.00655	0.0463	CbGeAlD
Apomorphine—HTR2A—urine—prostate cancer	0.00624	0.0441	CbGeAlD
Apomorphine—ADRA1D—prostate gland—prostate cancer	0.00603	0.0426	CbGeAlD
Apomorphine—DRD4—testis—prostate cancer	0.00503	0.0355	CbGeAlD
Apomorphine—CALY—lymph node—prostate cancer	0.00475	0.0335	CbGeAlD
Apomorphine—ADRA1D—epithelium—prostate cancer	0.00443	0.0313	CbGeAlD
Apomorphine—ADRA1B—renal system—prostate cancer	0.0042	0.0297	CbGeAlD
Apomorphine—ADRA1D—urethra—prostate cancer	0.00404	0.0285	CbGeAlD
Apomorphine—ADRA2C—prostate gland—prostate cancer	0.0033	0.0233	CbGeAlD
Apomorphine—ADRA2C—seminal vesicle—prostate cancer	0.00279	0.0197	CbGeAlD
Apomorphine—ADRA2A—prostate gland—prostate cancer	0.00263	0.0186	CbGeAlD
Apomorphine—HTR1A—renal system—prostate cancer	0.00256	0.0181	CbGeAlD
Apomorphine—ADRA2C—renal system—prostate cancer	0.00225	0.0159	CbGeAlD
Apomorphine—ADRA2A—seminal vesicle—prostate cancer	0.00223	0.0157	CbGeAlD
Apomorphine—ADRA2C—urethra—prostate cancer	0.00221	0.0156	CbGeAlD
Apomorphine—ADRA2A—urethra—prostate cancer	0.00176	0.0125	CbGeAlD
Apomorphine—HTR2A—epithelium—prostate cancer	0.00165	0.0116	CbGeAlD
Apomorphine—HTR2A—renal system—prostate cancer	0.00153	0.0108	CbGeAlD
Apomorphine—DRD2—testis—prostate cancer	0.0015	0.0106	CbGeAlD
Apomorphine—ADRA2C—testis—prostate cancer	0.00145	0.0103	CbGeAlD
Apomorphine—HTR2B—lymph node—prostate cancer	0.00134	0.00946	CbGeAlD
Apomorphine—ADRA2A—testis—prostate cancer	0.00116	0.0082	CbGeAlD
Apomorphine—ADRA2C—lymph node—prostate cancer	0.00105	0.00745	CbGeAlD
Apomorphine—HTR2A—testis—prostate cancer	0.000987	0.00697	CbGeAlD
Apomorphine—ADRA2A—lymph node—prostate cancer	0.000841	0.00594	CbGeAlD
Apomorphine—Insomnia—Conjugated Estrogens—prostate cancer	0.000786	0.00146	CcSEcCtD
Apomorphine—Dyspnoea—Goserelin—prostate cancer	0.000782	0.00146	CcSEcCtD
Apomorphine—Somnolence—Goserelin—prostate cancer	0.00078	0.00145	CcSEcCtD
Apomorphine—Injection site reaction—Doxorubicin—prostate cancer	0.000779	0.00145	CcSEcCtD
Apomorphine—Dyspnoea—Conjugated Estrogens—prostate cancer	0.000775	0.00144	CcSEcCtD
Apomorphine—Somnolence—Conjugated Estrogens—prostate cancer	0.000773	0.00144	CcSEcCtD
Apomorphine—Back pain—Mitoxantrone—prostate cancer	0.000768	0.00143	CcSEcCtD
Apomorphine—Psychotic disorder—Prednisone—prostate cancer	0.000768	0.00143	CcSEcCtD
Apomorphine—Angina pectoris—Docetaxel—prostate cancer	0.000767	0.00143	CcSEcCtD
Apomorphine—Ecchymosis—Epirubicin—prostate cancer	0.000766	0.00143	CcSEcCtD
Apomorphine—Asthenia—Ethinyl Estradiol—prostate cancer	0.000765	0.00142	CcSEcCtD
Apomorphine—Syncope—Estradiol—prostate cancer	0.000764	0.00142	CcSEcCtD
Apomorphine—Fatigue—Goserelin—prostate cancer	0.000756	0.00141	CcSEcCtD
Apomorphine—Pruritus—Ethinyl Estradiol—prostate cancer	0.000754	0.0014	CcSEcCtD
Apomorphine—Constipation—Goserelin—prostate cancer	0.00075	0.0014	CcSEcCtD
Apomorphine—Fatigue—Conjugated Estrogens—prostate cancer	0.000749	0.00139	CcSEcCtD
Apomorphine—Nausea—Bicalutamide—prostate cancer	0.000749	0.00139	CcSEcCtD
Apomorphine—Loss of consciousness—Estradiol—prostate cancer	0.000749	0.00139	CcSEcCtD
Apomorphine—Constipation—Conjugated Estrogens—prostate cancer	0.000743	0.00138	CcSEcCtD
Apomorphine—Sweating increased—Capecitabine—prostate cancer	0.000743	0.00138	CcSEcCtD
Apomorphine—Angina pectoris—Capecitabine—prostate cancer	0.000743	0.00138	CcSEcCtD
Apomorphine—Diarrhoea—Ethinyl Estradiol—prostate cancer	0.000729	0.00136	CcSEcCtD
Apomorphine—Arthralgia—Estradiol—prostate cancer	0.000726	0.00135	CcSEcCtD
Apomorphine—Chest pain—Estradiol—prostate cancer	0.000726	0.00135	CcSEcCtD
Apomorphine—Anxiety—Estradiol—prostate cancer	0.000723	0.00135	CcSEcCtD
Apomorphine—Feeling abnormal—Goserelin—prostate cancer	0.000723	0.00135	CcSEcCtD
Apomorphine—Ecchymosis—Doxorubicin—prostate cancer	0.000709	0.00132	CcSEcCtD
Apomorphine—Pneumonia—Docetaxel—prostate cancer	0.000707	0.00132	CcSEcCtD
Apomorphine—Dizziness—Ethinyl Estradiol—prostate cancer	0.000705	0.00131	CcSEcCtD
Apomorphine—Flushing—Etoposide—prostate cancer	0.000704	0.00131	CcSEcCtD
Apomorphine—Confusional state—Estradiol—prostate cancer	0.000701	0.00131	CcSEcCtD
Apomorphine—Oedema—Estradiol—prostate cancer	0.000696	0.00129	CcSEcCtD
Apomorphine—Shock—Estradiol—prostate cancer	0.000684	0.00127	CcSEcCtD
Apomorphine—Pneumonia—Capecitabine—prostate cancer	0.000684	0.00127	CcSEcCtD
Apomorphine—Cardiac failure congestive—Epirubicin—prostate cancer	0.000678	0.00126	CcSEcCtD
Apomorphine—Vomiting—Ethinyl Estradiol—prostate cancer	0.000678	0.00126	CcSEcCtD
Apomorphine—Chest pain—Mitoxantrone—prostate cancer	0.000676	0.00126	CcSEcCtD
Apomorphine—Arthralgia—Mitoxantrone—prostate cancer	0.000676	0.00126	CcSEcCtD
Apomorphine—Anxiety—Mitoxantrone—prostate cancer	0.000674	0.00125	CcSEcCtD
Apomorphine—Hyperhidrosis—Estradiol—prostate cancer	0.000672	0.00125	CcSEcCtD
Apomorphine—Headache—Ethinyl Estradiol—prostate cancer	0.000668	0.00124	CcSEcCtD
Apomorphine—Sweating increased—Prednisone—prostate cancer	0.000662	0.00123	CcSEcCtD
Apomorphine—Urinary tract infection—Capecitabine—prostate cancer	0.000661	0.00123	CcSEcCtD
Apomorphine—Confusional state—Mitoxantrone—prostate cancer	0.000653	0.00122	CcSEcCtD
Apomorphine—Oedema—Mitoxantrone—prostate cancer	0.000648	0.00121	CcSEcCtD
Apomorphine—Back pain—Etoposide—prostate cancer	0.000639	0.00119	CcSEcCtD
Apomorphine—Shock—Mitoxantrone—prostate cancer	0.000638	0.00119	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Estradiol—prostate cancer	0.000634	0.00118	CcSEcCtD
Apomorphine—Nausea—Ethinyl Estradiol—prostate cancer	0.000633	0.00118	CcSEcCtD
Apomorphine—Asthenia—Goserelin—prostate cancer	0.00063	0.00117	CcSEcCtD
Apomorphine—Insomnia—Estradiol—prostate cancer	0.000629	0.00117	CcSEcCtD
Apomorphine—Cardiac failure congestive—Doxorubicin—prostate cancer	0.000627	0.00117	CcSEcCtD
Apomorphine—Hyperhidrosis—Mitoxantrone—prostate cancer	0.000627	0.00117	CcSEcCtD
Apomorphine—Asthenia—Conjugated Estrogens—prostate cancer	0.000624	0.00116	CcSEcCtD
Apomorphine—Pruritus—Goserelin—prostate cancer	0.000621	0.00116	CcSEcCtD
Apomorphine—Dyspnoea—Estradiol—prostate cancer	0.00062	0.00115	CcSEcCtD
Apomorphine—Somnolence—Estradiol—prostate cancer	0.000618	0.00115	CcSEcCtD
Apomorphine—Pruritus—Conjugated Estrogens—prostate cancer	0.000615	0.00114	CcSEcCtD
Apomorphine—Pain in extremity—Epirubicin—prostate cancer	0.000615	0.00114	CcSEcCtD
Apomorphine—Hypotension—Mitoxantrone—prostate cancer	0.000606	0.00113	CcSEcCtD
Apomorphine—Diarrhoea—Goserelin—prostate cancer	0.0006	0.00112	CcSEcCtD
Apomorphine—Fatigue—Estradiol—prostate cancer	0.0006	0.00112	CcSEcCtD
Apomorphine—Constipation—Estradiol—prostate cancer	0.000595	0.00111	CcSEcCtD
Apomorphine—Diarrhoea—Conjugated Estrogens—prostate cancer	0.000595	0.00111	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Mitoxantrone—prostate cancer	0.00059	0.0011	CcSEcCtD
Apomorphine—Flushing—Docetaxel—prostate cancer	0.000585	0.00109	CcSEcCtD
Apomorphine—Loss of consciousness—Etoposide—prostate cancer	0.000581	0.00108	CcSEcCtD
Apomorphine—Dizziness—Goserelin—prostate cancer	0.00058	0.00108	CcSEcCtD
Apomorphine—Dyspnoea—Mitoxantrone—prostate cancer	0.000578	0.00108	CcSEcCtD
Apomorphine—Somnolence—Mitoxantrone—prostate cancer	0.000576	0.00107	CcSEcCtD
Apomorphine—Dizziness—Conjugated Estrogens—prostate cancer	0.000575	0.00107	CcSEcCtD
Apomorphine—Feeling abnormal—Estradiol—prostate cancer	0.000573	0.00107	CcSEcCtD
Apomorphine—Dehydration—Epirubicin—prostate cancer	0.000572	0.00106	CcSEcCtD
Apomorphine—Pain in extremity—Doxorubicin—prostate cancer	0.000569	0.00106	CcSEcCtD
Apomorphine—Flushing—Capecitabine—prostate cancer	0.000567	0.00105	CcSEcCtD
Apomorphine—Chest pain—Etoposide—prostate cancer	0.000562	0.00105	CcSEcCtD
Apomorphine—Orthostatic hypotension—Epirubicin—prostate cancer	0.000562	0.00105	CcSEcCtD
Apomorphine—Fatigue—Mitoxantrone—prostate cancer	0.000559	0.00104	CcSEcCtD
Apomorphine—Vomiting—Goserelin—prostate cancer	0.000558	0.00104	CcSEcCtD
Apomorphine—Constipation—Mitoxantrone—prostate cancer	0.000554	0.00103	CcSEcCtD
Apomorphine—Vomiting—Conjugated Estrogens—prostate cancer	0.000553	0.00103	CcSEcCtD
Apomorphine—Mental disorder—Docetaxel—prostate cancer	0.000552	0.00103	CcSEcCtD
Apomorphine—Nasopharyngitis—Epirubicin—prostate cancer	0.00055	0.00102	CcSEcCtD
Apomorphine—Headache—Goserelin—prostate cancer	0.00055	0.00102	CcSEcCtD
Apomorphine—Headache—Conjugated Estrogens—prostate cancer	0.000544	0.00101	CcSEcCtD
Apomorphine—Confusional state—Etoposide—prostate cancer	0.000544	0.00101	CcSEcCtD
Apomorphine—Hallucination—Prednisone—prostate cancer	0.000541	0.00101	CcSEcCtD
Apomorphine—Mental disorder—Capecitabine—prostate cancer	0.000535	0.000996	CcSEcCtD
Apomorphine—Feeling abnormal—Mitoxantrone—prostate cancer	0.000534	0.000994	CcSEcCtD
Apomorphine—Back pain—Docetaxel—prostate cancer	0.000531	0.000989	CcSEcCtD
Apomorphine—Dehydration—Doxorubicin—prostate cancer	0.000529	0.000985	CcSEcCtD
Apomorphine—Nausea—Goserelin—prostate cancer	0.000521	0.00097	CcSEcCtD
Apomorphine—Hyperhidrosis—Etoposide—prostate cancer	0.000521	0.00097	CcSEcCtD
Apomorphine—Orthostatic hypotension—Doxorubicin—prostate cancer	0.00052	0.000967	CcSEcCtD
Apomorphine—Angina pectoris—Epirubicin—prostate cancer	0.000518	0.000964	CcSEcCtD
Apomorphine—Nausea—Conjugated Estrogens—prostate cancer	0.000516	0.000961	CcSEcCtD
Apomorphine—Back pain—Capecitabine—prostate cancer	0.000514	0.000957	CcSEcCtD
Apomorphine—Nasopharyngitis—Doxorubicin—prostate cancer	0.000509	0.000947	CcSEcCtD
Apomorphine—Flushing—Prednisone—prostate cancer	0.000505	0.00094	CcSEcCtD
Apomorphine—Hypotension—Etoposide—prostate cancer	0.000504	0.000938	CcSEcCtD
Apomorphine—Asthenia—Estradiol—prostate cancer	0.000499	0.000929	CcSEcCtD
Apomorphine—Syncope—Docetaxel—prostate cancer	0.000492	0.000916	CcSEcCtD
Apomorphine—Pruritus—Estradiol—prostate cancer	0.000492	0.000916	CcSEcCtD
Apomorphine—Loss of consciousness—Docetaxel—prostate cancer	0.000482	0.000898	CcSEcCtD
Apomorphine—Dyspnoea—Etoposide—prostate cancer	0.000481	0.000895	CcSEcCtD
Apomorphine—Somnolence—Etoposide—prostate cancer	0.000479	0.000892	CcSEcCtD
Apomorphine—Angina pectoris—Doxorubicin—prostate cancer	0.000479	0.000892	CcSEcCtD
Apomorphine—Syncope—Capecitabine—prostate cancer	0.000477	0.000887	CcSEcCtD
Apomorphine—Pneumonia—Epirubicin—prostate cancer	0.000477	0.000887	CcSEcCtD
Apomorphine—Mental disorder—Prednisone—prostate cancer	0.000476	0.000887	CcSEcCtD
Apomorphine—Diarrhoea—Estradiol—prostate cancer	0.000476	0.000886	CcSEcCtD
Apomorphine—Drowsiness—Epirubicin—prostate cancer	0.000474	0.000882	CcSEcCtD
Apomorphine—Arthralgia—Docetaxel—prostate cancer	0.000467	0.00087	CcSEcCtD
Apomorphine—Chest pain—Docetaxel—prostate cancer	0.000467	0.00087	CcSEcCtD
Apomorphine—Loss of consciousness—Capecitabine—prostate cancer	0.000467	0.00087	CcSEcCtD
Apomorphine—Asthenia—Mitoxantrone—prostate cancer	0.000465	0.000866	CcSEcCtD
Apomorphine—Fatigue—Etoposide—prostate cancer	0.000465	0.000865	CcSEcCtD
Apomorphine—Constipation—Etoposide—prostate cancer	0.000461	0.000858	CcSEcCtD
Apomorphine—Urinary tract infection—Epirubicin—prostate cancer	0.000461	0.000857	CcSEcCtD
Apomorphine—Dizziness—Estradiol—prostate cancer	0.00046	0.000856	CcSEcCtD
Apomorphine—Arthralgia—Capecitabine—prostate cancer	0.000452	0.000842	CcSEcCtD
Apomorphine—Chest pain—Capecitabine—prostate cancer	0.000452	0.000842	CcSEcCtD
Apomorphine—Confusional state—Docetaxel—prostate cancer	0.000452	0.000841	CcSEcCtD
Apomorphine—Anxiety—Capecitabine—prostate cancer	0.000451	0.000839	CcSEcCtD
Apomorphine—Oedema—Docetaxel—prostate cancer	0.000448	0.000834	CcSEcCtD
Apomorphine—Feeling abnormal—Etoposide—prostate cancer	0.000444	0.000827	CcSEcCtD
Apomorphine—Diarrhoea—Mitoxantrone—prostate cancer	0.000443	0.000826	CcSEcCtD
Apomorphine—Vomiting—Estradiol—prostate cancer	0.000442	0.000823	CcSEcCtD
Apomorphine—Pneumonia—Doxorubicin—prostate cancer	0.000441	0.000821	CcSEcCtD
Apomorphine—Shock—Docetaxel—prostate cancer	0.000441	0.000821	CcSEcCtD
Apomorphine—Drowsiness—Doxorubicin—prostate cancer	0.000438	0.000816	CcSEcCtD
Apomorphine—Confusional state—Capecitabine—prostate cancer	0.000437	0.000814	CcSEcCtD
Apomorphine—Headache—Estradiol—prostate cancer	0.000436	0.000811	CcSEcCtD
Apomorphine—Oedema—Capecitabine—prostate cancer	0.000434	0.000808	CcSEcCtD
Apomorphine—Shock—Capecitabine—prostate cancer	0.000427	0.000794	CcSEcCtD
Apomorphine—Urinary tract infection—Doxorubicin—prostate cancer	0.000426	0.000793	CcSEcCtD
Apomorphine—Syncope—Prednisone—prostate cancer	0.000425	0.00079	CcSEcCtD
Apomorphine—Hyperhidrosis—Capecitabine—prostate cancer	0.000419	0.000781	CcSEcCtD
Apomorphine—Hypotension—Docetaxel—prostate cancer	0.000419	0.000779	CcSEcCtD
Apomorphine—Loss of consciousness—Prednisone—prostate cancer	0.000416	0.000775	CcSEcCtD
Apomorphine—Nausea—Estradiol—prostate cancer	0.000413	0.000769	CcSEcCtD
Apomorphine—Vomiting—Mitoxantrone—prostate cancer	0.000412	0.000767	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Docetaxel—prostate cancer	0.000408	0.00076	CcSEcCtD
Apomorphine—Headache—Mitoxantrone—prostate cancer	0.000406	0.000756	CcSEcCtD
Apomorphine—Hypotension—Capecitabine—prostate cancer	0.000405	0.000755	CcSEcCtD
Apomorphine—Insomnia—Docetaxel—prostate cancer	0.000405	0.000754	CcSEcCtD
Apomorphine—Arthralgia—Prednisone—prostate cancer	0.000403	0.00075	CcSEcCtD
Apomorphine—Anxiety—Prednisone—prostate cancer	0.000402	0.000748	CcSEcCtD
Apomorphine—Dyspnoea—Docetaxel—prostate cancer	0.000399	0.000744	CcSEcCtD
Apomorphine—Somnolence—Docetaxel—prostate cancer	0.000398	0.000742	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Capecitabine—prostate cancer	0.000395	0.000736	CcSEcCtD
Apomorphine—Flushing—Epirubicin—prostate cancer	0.000395	0.000735	CcSEcCtD
Apomorphine—Insomnia—Capecitabine—prostate cancer	0.000392	0.00073	CcSEcCtD
Apomorphine—Asthenia—Etoposide—prostate cancer	0.000387	0.00072	CcSEcCtD
Apomorphine—Dyspnoea—Capecitabine—prostate cancer	0.000387	0.00072	CcSEcCtD
Apomorphine—Oedema—Prednisone—prostate cancer	0.000386	0.000719	CcSEcCtD
Apomorphine—Fatigue—Docetaxel—prostate cancer	0.000386	0.000719	CcSEcCtD
Apomorphine—Nausea—Mitoxantrone—prostate cancer	0.000385	0.000717	CcSEcCtD
Apomorphine—Constipation—Docetaxel—prostate cancer	0.000383	0.000713	CcSEcCtD
Apomorphine—Pruritus—Etoposide—prostate cancer	0.000381	0.00071	CcSEcCtD
Apomorphine—Shock—Prednisone—prostate cancer	0.00038	0.000708	CcSEcCtD
Apomorphine—Fatigue—Capecitabine—prostate cancer	0.000374	0.000696	CcSEcCtD
Apomorphine—Hyperhidrosis—Prednisone—prostate cancer	0.000374	0.000695	CcSEcCtD
Apomorphine—Mental disorder—Epirubicin—prostate cancer	0.000373	0.000694	CcSEcCtD
Apomorphine—Constipation—Capecitabine—prostate cancer	0.000371	0.000691	CcSEcCtD
Apomorphine—Feeling abnormal—Docetaxel—prostate cancer	0.000369	0.000687	CcSEcCtD
Apomorphine—Diarrhoea—Etoposide—prostate cancer	0.000369	0.000687	CcSEcCtD
Apomorphine—Flushing—Doxorubicin—prostate cancer	0.000365	0.00068	CcSEcCtD
Apomorphine—Back pain—Epirubicin—prostate cancer	0.000358	0.000667	CcSEcCtD
Apomorphine—Feeling abnormal—Capecitabine—prostate cancer	0.000357	0.000665	CcSEcCtD
Apomorphine—Dizziness—Etoposide—prostate cancer	0.000356	0.000664	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Prednisone—prostate cancer	0.000352	0.000655	CcSEcCtD
Apomorphine—Insomnia—Prednisone—prostate cancer	0.000349	0.000651	CcSEcCtD
Apomorphine—Mental disorder—Doxorubicin—prostate cancer	0.000345	0.000642	CcSEcCtD
Apomorphine—Vomiting—Etoposide—prostate cancer	0.000343	0.000638	CcSEcCtD
Apomorphine—Headache—Etoposide—prostate cancer	0.000338	0.000629	CcSEcCtD
Apomorphine—Fatigue—Prednisone—prostate cancer	0.000333	0.00062	CcSEcCtD
Apomorphine—Syncope—Epirubicin—prostate cancer	0.000332	0.000618	CcSEcCtD
Apomorphine—Back pain—Doxorubicin—prostate cancer	0.000331	0.000617	CcSEcCtD
Apomorphine—Constipation—Prednisone—prostate cancer	0.00033	0.000615	CcSEcCtD
Apomorphine—Loss of consciousness—Epirubicin—prostate cancer	0.000325	0.000606	CcSEcCtD
Apomorphine—Asthenia—Docetaxel—prostate cancer	0.000321	0.000598	CcSEcCtD
Apomorphine—Nausea—Etoposide—prostate cancer	0.00032	0.000596	CcSEcCtD
Apomorphine—Feeling abnormal—Prednisone—prostate cancer	0.000318	0.000593	CcSEcCtD
Apomorphine—Pruritus—Docetaxel—prostate cancer	0.000317	0.00059	CcSEcCtD
Apomorphine—Chest pain—Epirubicin—prostate cancer	0.000315	0.000587	CcSEcCtD
Apomorphine—Arthralgia—Epirubicin—prostate cancer	0.000315	0.000587	CcSEcCtD
Apomorphine—Anxiety—Epirubicin—prostate cancer	0.000314	0.000585	CcSEcCtD
Apomorphine—Asthenia—Capecitabine—prostate cancer	0.000311	0.000579	CcSEcCtD
Apomorphine—Syncope—Doxorubicin—prostate cancer	0.000307	0.000572	CcSEcCtD
Apomorphine—Pruritus—Capecitabine—prostate cancer	0.000307	0.000571	CcSEcCtD
Apomorphine—Diarrhoea—Docetaxel—prostate cancer	0.000307	0.000571	CcSEcCtD
Apomorphine—Confusional state—Epirubicin—prostate cancer	0.000305	0.000567	CcSEcCtD
Apomorphine—Oedema—Epirubicin—prostate cancer	0.000302	0.000563	CcSEcCtD
Apomorphine—Loss of consciousness—Doxorubicin—prostate cancer	0.000301	0.000561	CcSEcCtD
Apomorphine—Shock—Epirubicin—prostate cancer	0.000297	0.000553	CcSEcCtD
Apomorphine—Diarrhoea—Capecitabine—prostate cancer	0.000297	0.000553	CcSEcCtD
Apomorphine—Dizziness—Docetaxel—prostate cancer	0.000296	0.000552	CcSEcCtD
Apomorphine—Hyperhidrosis—Epirubicin—prostate cancer	0.000292	0.000544	CcSEcCtD
Apomorphine—Chest pain—Doxorubicin—prostate cancer	0.000292	0.000543	CcSEcCtD
Apomorphine—Arthralgia—Doxorubicin—prostate cancer	0.000292	0.000543	CcSEcCtD
Apomorphine—Anxiety—Doxorubicin—prostate cancer	0.000291	0.000541	CcSEcCtD
Apomorphine—Dizziness—Capecitabine—prostate cancer	0.000287	0.000534	CcSEcCtD
Apomorphine—Vomiting—Docetaxel—prostate cancer	0.000285	0.00053	CcSEcCtD
Apomorphine—Hypotension—Epirubicin—prostate cancer	0.000282	0.000526	CcSEcCtD
Apomorphine—Confusional state—Doxorubicin—prostate cancer	0.000282	0.000525	CcSEcCtD
Apomorphine—Headache—Docetaxel—prostate cancer	0.000281	0.000523	CcSEcCtD
Apomorphine—Oedema—Doxorubicin—prostate cancer	0.00028	0.000521	CcSEcCtD
Apomorphine—Asthenia—Prednisone—prostate cancer	0.000277	0.000516	CcSEcCtD
Apomorphine—Vomiting—Capecitabine—prostate cancer	0.000276	0.000513	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Epirubicin—prostate cancer	0.000275	0.000513	CcSEcCtD
Apomorphine—Shock—Doxorubicin—prostate cancer	0.000275	0.000512	CcSEcCtD
Apomorphine—Pruritus—Prednisone—prostate cancer	0.000273	0.000509	CcSEcCtD
Apomorphine—Insomnia—Epirubicin—prostate cancer	0.000273	0.000509	CcSEcCtD
Apomorphine—Headache—Capecitabine—prostate cancer	0.000272	0.000506	CcSEcCtD
Apomorphine—Hyperhidrosis—Doxorubicin—prostate cancer	0.00027	0.000503	CcSEcCtD
Apomorphine—Dyspnoea—Epirubicin—prostate cancer	0.000269	0.000502	CcSEcCtD
Apomorphine—Somnolence—Epirubicin—prostate cancer	0.000269	0.0005	CcSEcCtD
Apomorphine—Nausea—Docetaxel—prostate cancer	0.000266	0.000495	CcSEcCtD
Apomorphine—Diarrhoea—Prednisone—prostate cancer	0.000264	0.000492	CcSEcCtD
Apomorphine—Hypotension—Doxorubicin—prostate cancer	0.000261	0.000486	CcSEcCtD
Apomorphine—Fatigue—Epirubicin—prostate cancer	0.000261	0.000485	CcSEcCtD
Apomorphine—Constipation—Epirubicin—prostate cancer	0.000258	0.000481	CcSEcCtD
Apomorphine—Nausea—Capecitabine—prostate cancer	0.000258	0.00048	CcSEcCtD
Apomorphine—Dizziness—Prednisone—prostate cancer	0.000255	0.000476	CcSEcCtD
Apomorphine—Musculoskeletal discomfort—Doxorubicin—prostate cancer	0.000255	0.000474	CcSEcCtD
Apomorphine—Insomnia—Doxorubicin—prostate cancer	0.000253	0.000471	CcSEcCtD
Apomorphine—Dyspnoea—Doxorubicin—prostate cancer	0.000249	0.000464	CcSEcCtD
Apomorphine—Feeling abnormal—Epirubicin—prostate cancer	0.000249	0.000464	CcSEcCtD
Apomorphine—Somnolence—Doxorubicin—prostate cancer	0.000249	0.000463	CcSEcCtD
Apomorphine—Vomiting—Prednisone—prostate cancer	0.000246	0.000457	CcSEcCtD
Apomorphine—Headache—Prednisone—prostate cancer	0.000242	0.000451	CcSEcCtD
Apomorphine—Fatigue—Doxorubicin—prostate cancer	0.000241	0.000449	CcSEcCtD
Apomorphine—Constipation—Doxorubicin—prostate cancer	0.000239	0.000445	CcSEcCtD
Apomorphine—Feeling abnormal—Doxorubicin—prostate cancer	0.00023	0.000429	CcSEcCtD
Apomorphine—Nausea—Prednisone—prostate cancer	0.000229	0.000427	CcSEcCtD
Apomorphine—Asthenia—Epirubicin—prostate cancer	0.000217	0.000404	CcSEcCtD
Apomorphine—Pruritus—Epirubicin—prostate cancer	0.000214	0.000398	CcSEcCtD
Apomorphine—Diarrhoea—Epirubicin—prostate cancer	0.000207	0.000385	CcSEcCtD
Apomorphine—Asthenia—Doxorubicin—prostate cancer	0.000201	0.000373	CcSEcCtD
Apomorphine—Dizziness—Epirubicin—prostate cancer	0.0002	0.000372	CcSEcCtD
Apomorphine—Pruritus—Doxorubicin—prostate cancer	0.000198	0.000368	CcSEcCtD
Apomorphine—Vomiting—Epirubicin—prostate cancer	0.000192	0.000358	CcSEcCtD
Apomorphine—Diarrhoea—Doxorubicin—prostate cancer	0.000191	0.000356	CcSEcCtD
Apomorphine—Headache—Epirubicin—prostate cancer	0.000189	0.000352	CcSEcCtD
Apomorphine—Dizziness—Doxorubicin—prostate cancer	0.000185	0.000344	CcSEcCtD
Apomorphine—Nausea—Epirubicin—prostate cancer	0.000179	0.000334	CcSEcCtD
Apomorphine—Vomiting—Doxorubicin—prostate cancer	0.000178	0.000331	CcSEcCtD
Apomorphine—Headache—Doxorubicin—prostate cancer	0.000175	0.000326	CcSEcCtD
Apomorphine—Nausea—Doxorubicin—prostate cancer	0.000166	0.000309	CcSEcCtD
Apomorphine—ADRA2A—Signaling Pathways—MAP2K1—prostate cancer	8.76e-06	2.73e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—VEGFA—prostate cancer	8.76e-06	2.73e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—EGFR—prostate cancer	8.75e-06	2.72e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—PIK3CA—prostate cancer	8.74e-06	2.72e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MDM2—prostate cancer	8.71e-06	2.71e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CD—prostate cancer	8.7e-06	2.71e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MMP9—prostate cancer	8.69e-06	2.7e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—STAT3—prostate cancer	8.67e-06	2.7e-05	CbGpPWpGaD
Apomorphine—ADRA2C—GPCR downstream signaling—AKT1—prostate cancer	8.67e-06	2.7e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—CDKN1A—prostate cancer	8.66e-06	2.69e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—VEGFA—prostate cancer	8.64e-06	2.69e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—VEGFA—prostate cancer	8.64e-06	2.69e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CCND1—prostate cancer	8.64e-06	2.69e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PTEN—prostate cancer	8.64e-06	2.69e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CDKN1B—prostate cancer	8.62e-06	2.68e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—PIK3CA—prostate cancer	8.62e-06	2.68e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SERPINE1—prostate cancer	8.6e-06	2.68e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—PIK3CA—prostate cancer	8.6e-06	2.68e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CCND1—prostate cancer	8.59e-06	2.67e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CASP3—prostate cancer	8.59e-06	2.67e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—ERBB2—prostate cancer	8.58e-06	2.67e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—KRAS—prostate cancer	8.58e-06	2.67e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IL2—prostate cancer	8.57e-06	2.67e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MDM2—prostate cancer	8.57e-06	2.67e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—STAT3—prostate cancer	8.56e-06	2.66e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—STAT3—prostate cancer	8.56e-06	2.66e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CTNNB1—prostate cancer	8.55e-06	2.66e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—MYC—prostate cancer	8.54e-06	2.66e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—IL6—prostate cancer	8.53e-06	2.66e-05	CbGpPWpGaD
Apomorphine—ADRA1B—GPCR downstream signaling—AKT1—prostate cancer	8.53e-06	2.65e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TGFB1—prostate cancer	8.52e-06	2.65e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—KRAS—prostate cancer	8.52e-06	2.65e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CTNNB1—prostate cancer	8.51e-06	2.65e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CB—prostate cancer	8.47e-06	2.64e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CASP3—prostate cancer	8.45e-06	2.63e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—ERBB2—prostate cancer	8.45e-06	2.63e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL2—prostate cancer	8.44e-06	2.63e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling by GPCR—AKT1—prostate cancer	8.43e-06	2.62e-05	CbGpPWpGaD
Apomorphine—DRD5—Signaling Pathways—AKT1—prostate cancer	8.41e-06	2.62e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—KRAS—prostate cancer	8.4e-06	2.62e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—IL6—prostate cancer	8.4e-06	2.61e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MMP9—prostate cancer	8.39e-06	2.61e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CCND1—prostate cancer	8.36e-06	2.6e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—EGFR—prostate cancer	8.36e-06	2.6e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—CDKN1A—prostate cancer	8.36e-06	2.6e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MMP9—prostate cancer	8.34e-06	2.6e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PTEN—prostate cancer	8.34e-06	2.59e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CB—prostate cancer	8.33e-06	2.59e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—FGF2—prostate cancer	8.33e-06	2.59e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—CDKN1A—prostate cancer	8.31e-06	2.59e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PTEN—prostate cancer	8.29e-06	2.58e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CTNNB1—prostate cancer	8.28e-06	2.58e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—KRAS—prostate cancer	8.27e-06	2.57e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—EP300—prostate cancer	8.24e-06	2.56e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CCND1—prostate cancer	8.23e-06	2.56e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—NOS3—prostate cancer	8.21e-06	2.56e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CTNNB1—prostate cancer	8.15e-06	2.54e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CXCL8—prostate cancer	8.14e-06	2.53e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling by GPCR—AKT1—prostate cancer	8.13e-06	2.53e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MMP9—prostate cancer	8.11e-06	2.53e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling by GPCR—AKT1—prostate cancer	8.09e-06	2.52e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—CDKN1A—prostate cancer	8.09e-06	2.52e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PTEN—prostate cancer	8.07e-06	2.51e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—MYC—prostate cancer	8.06e-06	2.51e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TGFB1—prostate cancer	8.04e-06	2.5e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CXCL8—prostate cancer	8.01e-06	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—SRC—prostate cancer	8.01e-06	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MMP9—prostate cancer	7.99e-06	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—JAK2—prostate cancer	7.98e-06	2.49e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—CDKN1A—prostate cancer	7.96e-06	2.48e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—EP300—prostate cancer	7.95e-06	2.47e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—MYC—prostate cancer	7.95e-06	2.47e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CDKN1B—prostate cancer	7.95e-06	2.47e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—MYC—prostate cancer	7.95e-06	2.47e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PTEN—prostate cancer	7.94e-06	2.47e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TGFB1—prostate cancer	7.93e-06	2.47e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TGFB1—prostate cancer	7.93e-06	2.47e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—EP300—prostate cancer	7.91e-06	2.46e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—KRAS—prostate cancer	7.89e-06	2.46e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—PIK3CA—prostate cancer	7.88e-06	2.45e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—EGFR—prostate cancer	7.88e-06	2.45e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling by GPCR—AKT1—prostate cancer	7.87e-06	2.45e-05	CbGpPWpGaD
Apomorphine—DRD2—GPCR downstream signaling—AKT1—prostate cancer	7.86e-06	2.45e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PTEN—prostate cancer	7.84e-06	2.44e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—PIK3CA—prostate cancer	7.83e-06	2.44e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CDKN1B—prostate cancer	7.82e-06	2.43e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—VEGFA—prostate cancer	7.8e-06	2.43e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MDM2—prostate cancer	7.79e-06	2.43e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CASP3—prostate cancer	7.79e-06	2.42e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL2—prostate cancer	7.78e-06	2.42e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—EGFR—prostate cancer	7.78e-06	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—EGFR—prostate cancer	7.78e-06	2.42e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling by GPCR—AKT1—prostate cancer	7.75e-06	2.41e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—IL6—prostate cancer	7.74e-06	2.41e-05	CbGpPWpGaD
Apomorphine—HTR2A—GPCR downstream signaling—AKT1—prostate cancer	7.74e-06	2.41e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—SRC—prostate cancer	7.73e-06	2.41e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—STAT3—prostate cancer	7.72e-06	2.4e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—PIK3CA—prostate cancer	7.72e-06	2.4e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—EP300—prostate cancer	7.69e-06	2.39e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—SRC—prostate cancer	7.69e-06	2.39e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—ERBB2—prostate cancer	7.68e-06	2.39e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CASP3—prostate cancer	7.67e-06	2.39e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL2—prostate cancer	7.65e-06	2.38e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—TP53—prostate cancer	7.63e-06	2.37e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—IL6—prostate cancer	7.62e-06	2.37e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—PIK3CA—prostate cancer	7.6e-06	2.36e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CCND1—prostate cancer	7.58e-06	2.36e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CB—prostate cancer	7.58e-06	2.36e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—EP300—prostate cancer	7.57e-06	2.36e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—VEGFA—prostate cancer	7.53e-06	2.34e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CTNNB1—prostate cancer	7.51e-06	2.34e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—VEGFA—prostate cancer	7.49e-06	2.33e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—SRC—prostate cancer	7.48e-06	2.33e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—EP300—prostate cancer	7.47e-06	2.33e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—TP53—prostate cancer	7.47e-06	2.32e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CCND1—prostate cancer	7.46e-06	2.32e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—STAT3—prostate cancer	7.46e-06	2.32e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—KRAS—prostate cancer	7.44e-06	2.32e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—STAT3—prostate cancer	7.42e-06	2.31e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CTNNB1—prostate cancer	7.39e-06	2.3e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—SRC—prostate cancer	7.36e-06	2.29e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MMP9—prostate cancer	7.36e-06	2.29e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—TP53—prostate cancer	7.35e-06	2.29e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—KRAS—prostate cancer	7.35e-06	2.29e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—KRAS—prostate cancer	7.35e-06	2.29e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—CDKN1A—prostate cancer	7.34e-06	2.28e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PTEN—prostate cancer	7.32e-06	2.28e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CXCL8—prostate cancer	7.29e-06	2.27e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—VEGFA—prostate cancer	7.29e-06	2.27e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—PIK3CA—prostate cancer	7.25e-06	2.26e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MMP9—prostate cancer	7.24e-06	2.25e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—CDKN1A—prostate cancer	7.22e-06	2.25e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—STAT3—prostate cancer	7.21e-06	2.25e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PTEN—prostate cancer	7.2e-06	2.24e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—MYC—prostate cancer	7.18e-06	2.23e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—VEGFA—prostate cancer	7.17e-06	2.23e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TGFB1—prostate cancer	7.16e-06	2.23e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling by GPCR—AKT1—prostate cancer	7.14e-06	2.22e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CDKN1B—prostate cancer	7.12e-06	2.21e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—STAT3—prostate cancer	7.1e-06	2.21e-05	CbGpPWpGaD
Apomorphine—ADRA2A—GPCR downstream signaling—AKT1—prostate cancer	7.04e-06	2.19e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling by GPCR—AKT1—prostate cancer	7.03e-06	2.19e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—EGFR—prostate cancer	7.02e-06	2.18e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—TP53—prostate cancer	7.02e-06	2.18e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—IL6—prostate cancer	6.98e-06	2.17e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—EP300—prostate cancer	6.98e-06	2.17e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CASP3—prostate cancer	6.97e-06	2.17e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL2—prostate cancer	6.96e-06	2.17e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—IL6—prostate cancer	6.93e-06	2.16e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—MYC—prostate cancer	6.93e-06	2.16e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TGFB1—prostate cancer	6.91e-06	2.15e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—MYC—prostate cancer	6.89e-06	2.15e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TGFB1—prostate cancer	6.88e-06	2.14e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—EP300—prostate cancer	6.87e-06	2.14e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—PIK3CA—prostate cancer	6.84e-06	2.13e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—IL6—prostate cancer	6.84e-06	2.13e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—PIK3CA—prostate cancer	6.81e-06	2.12e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CCND1—prostate cancer	6.79e-06	2.11e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—SRC—prostate cancer	6.79e-06	2.11e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—EGFR—prostate cancer	6.78e-06	2.11e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—PIK3CA—prostate cancer	6.75e-06	2.1e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—PIK3CA—prostate cancer	6.75e-06	2.1e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—EGFR—prostate cancer	6.74e-06	2.1e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—IL6—prostate cancer	6.73e-06	2.09e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CTNNB1—prostate cancer	6.72e-06	2.09e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—MYC—prostate cancer	6.7e-06	2.09e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TGFB1—prostate cancer	6.69e-06	2.08e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—SRC—prostate cancer	6.68e-06	2.08e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—KRAS—prostate cancer	6.63e-06	2.06e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—TP53—prostate cancer	6.62e-06	2.06e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—VEGFA—prostate cancer	6.61e-06	2.06e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—MYC—prostate cancer	6.6e-06	2.05e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MMP9—prostate cancer	6.59e-06	2.05e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TGFB1—prostate cancer	6.58e-06	2.05e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—CDKN1A—prostate cancer	6.57e-06	2.04e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—EGFR—prostate cancer	6.56e-06	2.04e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PTEN—prostate cancer	6.55e-06	2.04e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—STAT3—prostate cancer	6.55e-06	2.04e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—TP53—prostate cancer	6.53e-06	2.03e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—TP53—prostate cancer	6.53e-06	2.03e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—VEGFA—prostate cancer	6.51e-06	2.02e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—EGFR—prostate cancer	6.45e-06	2.01e-05	CbGpPWpGaD
Apomorphine—HTR1D—Signaling Pathways—AKT1—prostate cancer	6.44e-06	2e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—STAT3—prostate cancer	6.44e-06	2e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—IL6—prostate cancer	6.42e-06	2e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—KRAS—prostate cancer	6.4e-06	1.99e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling by GPCR—AKT1—prostate cancer	6.39e-06	1.99e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—KRAS—prostate cancer	6.37e-06	1.98e-05	CbGpPWpGaD
Apomorphine—HTR1B—Signaling Pathways—AKT1—prostate cancer	6.31e-06	1.96e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—EP300—prostate cancer	6.25e-06	1.94e-05	CbGpPWpGaD
Apomorphine—DRD4—Signaling Pathways—AKT1—prostate cancer	6.21e-06	1.93e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—KRAS—prostate cancer	6.19e-06	1.93e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—KRAS—prostate cancer	6.1e-06	1.9e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—PIK3CA—prostate cancer	6.09e-06	1.9e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—MYC—prostate cancer	6.08e-06	1.89e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—SRC—prostate cancer	6.08e-06	1.89e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TGFB1—prostate cancer	6.07e-06	1.89e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—IL6—prostate cancer	6.06e-06	1.89e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—MYC—prostate cancer	5.99e-06	1.86e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—IL6—prostate cancer	5.98e-06	1.86e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—IL6—prostate cancer	5.98e-06	1.86e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TGFB1—prostate cancer	5.97e-06	1.86e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—EGFR—prostate cancer	5.95e-06	1.85e-05	CbGpPWpGaD
Apomorphine—HTR2B—Signaling Pathways—AKT1—prostate cancer	5.92e-06	1.84e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—VEGFA—prostate cancer	5.92e-06	1.84e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—TP53—prostate cancer	5.89e-06	1.83e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—PIK3CA—prostate cancer	5.88e-06	1.83e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—STAT3—prostate cancer	5.86e-06	1.82e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—EGFR—prostate cancer	5.85e-06	1.82e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—PIK3CA—prostate cancer	5.85e-06	1.82e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—PIK3CA—prostate cancer	5.69e-06	1.77e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—TP53—prostate cancer	5.69e-06	1.77e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—TP53—prostate cancer	5.66e-06	1.76e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—KRAS—prostate cancer	5.62e-06	1.75e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—PIK3CA—prostate cancer	5.6e-06	1.74e-05	CbGpPWpGaD
Apomorphine—DRD1—Signaling Pathways—AKT1—prostate cancer	5.59e-06	1.74e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Metabolism—AKT1—prostate cancer	5.56e-06	1.73e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—KRAS—prostate cancer	5.53e-06	1.72e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—PIK3CA—prostate cancer	5.53e-06	1.72e-05	CbGpPWpGaD
Apomorphine—DRD3—Signaling Pathways—AKT1—prostate cancer	5.51e-06	1.72e-05	CbGpPWpGaD
Apomorphine—ADRA1D—Signaling Pathways—AKT1—prostate cancer	5.51e-06	1.72e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—TP53—prostate cancer	5.51e-06	1.71e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—MYC—prostate cancer	5.45e-06	1.69e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TGFB1—prostate cancer	5.43e-06	1.69e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—TP53—prostate cancer	5.42e-06	1.69e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—IL6—prostate cancer	5.39e-06	1.68e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—EGFR—prostate cancer	5.33e-06	1.66e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—IL6—prostate cancer	5.21e-06	1.62e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—IL6—prostate cancer	5.18e-06	1.61e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—PIK3CA—prostate cancer	5.16e-06	1.61e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—PIK3CA—prostate cancer	5.08e-06	1.58e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—IL6—prostate cancer	5.04e-06	1.57e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—KRAS—prostate cancer	5.03e-06	1.57e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—TP53—prostate cancer	5e-06	1.55e-05	CbGpPWpGaD
Apomorphine—ADRA2B—Signaling Pathways—AKT1—prostate cancer	4.98e-06	1.55e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—IL6—prostate cancer	4.96e-06	1.54e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—TP53—prostate cancer	4.92e-06	1.53e-05	CbGpPWpGaD
Apomorphine—HTR1A—Signaling Pathways—AKT1—prostate cancer	4.8e-06	1.5e-05	CbGpPWpGaD
Apomorphine—HTR2C—Signaling Pathways—AKT1—prostate cancer	4.78e-06	1.49e-05	CbGpPWpGaD
Apomorphine—ADRA2C—Signaling Pathways—AKT1—prostate cancer	4.65e-06	1.45e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—PIK3CA—prostate cancer	4.62e-06	1.44e-05	CbGpPWpGaD
Apomorphine—ADRA1B—Signaling Pathways—AKT1—prostate cancer	4.58e-06	1.42e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—IL6—prostate cancer	4.57e-06	1.42e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Metabolism—AKT1—prostate cancer	4.52e-06	1.41e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—IL6—prostate cancer	4.5e-06	1.4e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—TP53—prostate cancer	4.47e-06	1.39e-05	CbGpPWpGaD
Apomorphine—DRD2—Signaling Pathways—AKT1—prostate cancer	4.22e-06	1.31e-05	CbGpPWpGaD
Apomorphine—HTR2A—Signaling Pathways—AKT1—prostate cancer	4.15e-06	1.29e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—IL6—prostate cancer	4.09e-06	1.27e-05	CbGpPWpGaD
Apomorphine—ADRA2A—Signaling Pathways—AKT1—prostate cancer	3.78e-06	1.18e-05	CbGpPWpGaD
